Managers / Q2 2023 · view latest →
VK Services, LLC
CIK 0001501927 · 2128 SAND HILL ROAD, MENLO PARK, CA, 94025 · (650) 376-8526
Summary
Vk Services, LLC reported $880M in U.S.-listed holdings across 11 positions for Q2 2023.
The portfolio is heavily concentrated: Rocket Lab USA alone accounts for 51.0% of reported value.
The book was largely unchanged from Q1 2023.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Other · 85.0% · $748M
- Common Stock · 15.0% · $132M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2023 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| ROCKET LAB USA INC | HELD | +0 | 74.75M | +$147M | $449M |
| LANZATECH GLOBAL INC | HELD | +0 | 13.88M | +$41M | $95M |
| OSCROSCAR HEALTH INC | HELD | +0 | 11.70M | +$18M | $94M |
| VICARIOUS SURGICAL INC | HELD | +0 | 23.32M | −$8M | $42M |
| NANO X IMAGING LTD | HELD | +0 | 426.8K | +$4M | $7M |
| VELO3D INC | HELD | +0 | 30.35M | −$3M | $66M |
| PARDES BIOSCIENCES INC | HELD | +0 | 6.15M | +$3M | $11M |
| AFRMAFFIRM HLDGS INC | HELD | +0 | 600.8K | +$2M | $9M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2023
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | ROCKET LAB USA INC | COMMON STOCK | 50.97% | $449M | 74.75M |
| 2 | LANZATECH GLOBAL INC | COMMON STOCK | 10.77% | $95M | 13.88M |
| 3 | OSCROSCAR HEALTH INChistory → | CLASS A COMMON STOCK | 10.72% | $94M | 11.70M |
| 4 | BERKSHIRE GREY INC | CLASS A COMMON STOCK | 9.06% | $80M | 56.57M |
| 5 | VELO3D INC | COMMON STOCK | 7.45% | $66M | 30.35M |
| 6 | VICARIOUS SURGICAL INC | CLASS A COMMON STOCK | 4.36% | $38M | 20.96M |
| 7 | QSQUANTUMSCAPE CORPhistory → | CLASS A COMMON STOCK | 3.24% | $28M | 3.56M |
| 8 | PARDES BIOSCIENCES INC | COMMON STOCK | 1.27% | $11M | 6.15M |
| 9 | AFRMAFFIRM HLDGS INChistory → | CLASS A COMMON STOCK | 1.05% | $9M | 600.8K |
| 10 | NANO X IMAGING LTD | ORDINARY SHARES | 0.75% | $7M | 426.8K |
| 11 | PAGAYA TECHNOLOGIES LTD | CLASS A ORDINARY SHARES | 0.38% | $3M | 2.37M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $542,836 | 1 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | Under review | 2 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $404M | 3 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $770M | 2 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $388M | 2 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $849M | 2 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $455M | 5 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $410M | 7 | Aug 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $549M | 7 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $660M | 7 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $750M | 10 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $880M | 11 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $676M | 11 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $568M | 9 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $671M | 7 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $671M | 11 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $2.0B | 10 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $4.6B | 9 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $4.4B | 11 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $3.0B | 7 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $4.3B | 7 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $2.8B | 5 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $0 | 1 | May 5, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $209M | 1 | Jan 31, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $296M | 1 | Oct 25, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $617M | 1 | Jul 18, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $548M | 1 | Apr 23, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $268M | 1 | Feb 13, 2019 | 13F-HR | changes · EDGAR ↗ |
Other Included Managers
This filing reports holdings on behalf of 5 additional managers.
- Khosla Ventures Associates III, LLC028-20988
- Khosla Ventures Associates IV, LLC028-19200
- Khosla Ventures Associates V, LLC028-20985
- Khosla Ventures Seed Associates B, LLC028-20986
- Khosla Ventures Seed Associates C, LLC028-21418
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.